{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:26:52Z","timestamp":1786112812574,"version":"build-2736575974"},"reference-count":97,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.drudis.2026.104651","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:57:12Z","timestamp":1774583832000},"page":"104651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibiotic repurposing as alternative therapeutic strategies for cancer and Alzheimer\u2019s disease: A solution or conundrum?"],"prefix":"10.1016","volume":"31","author":[{"given":"Amber Lot Yee","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Wei","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0433-5070","authenticated-orcid":false,"given":"Keng Yoon","family":"Yeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104651_b0005","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.833005","article-title":"Repurposing of antibiotics: sense or non-sense","volume":"13","author":"Talat","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104651_b0010","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.3390\/cancers13133193","article-title":"Repurposing of antimicrobial agents for cancer therapy: what do we know?","volume":"13","author":"Pfab","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2026.104651_b0015","first-page":"447","article-title":"Parsing clinical success rates","volume":"15","author":"Mullard","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104651_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.684515","article-title":"Brief overview of approaches and challenges in new antibiotic development: a focus on drug repurposing","volume":"11","author":"Boyd","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.drudis.2026.104651_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.adcanc.2022.100065","article-title":"Repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancer","volume":"6","author":"Tripathi","year":"2022","journal-title":"Adv Cancer Biol Metastasis"},{"key":"10.1016\/j.drudis.2026.104651_b0030","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.18632\/oncotarget.3174","article-title":"Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease","volume":"6","author":"Lamb","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2026.104651_b0035","doi-asserted-by":"crossref","first-page":"56126","DOI":"10.18632\/oncotarget.18445","article-title":"Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for optimizing anti-angiogenic therapy","volume":"8","author":"De Francesco","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2026.104651_b0040","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/15384101.2016.1241929","article-title":"Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer","volume":"16","author":"Zhang","year":"2017","journal-title":"Cell Cycle"},{"key":"10.1016\/j.drudis.2026.104651_b0045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lab.2003.12.012","article-title":"Doxycycline inhibits cell proliferation and invasive potential: combination therapy with cyclooxygenase-2 inhibitor in human colorectal cancer cells","volume":"143","author":"Onoda","year":"2004","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.drudis.2026.104651_b0050","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1476-5381.2010.00746.x","article-title":"Activation of c\u2010Jun N\u2010terminal kinase is essential for mitochondrial membrane potential change and apoptosis induced by doxycycline in melanoma cells","volume":"160","author":"Shieh","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104651_b0055","doi-asserted-by":"crossref","first-page":"14005","DOI":"10.18632\/oncotarget.4159","article-title":"Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: implications for more effective radiation therapy","volume":"6","author":"Lamb","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2026.104651_b0060","article-title":"Doxycycline induces apoptosis and inhibits proliferation and invasion of human cervical carcinoma stem cells","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104651_b0065","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1139\/cjpp-2015-0481","article-title":"Doxycycline inhibits proliferation and induces apoptosis of both human papillomavirus positive and negative cervical cancer cell lines","volume":"94","author":"Zhao","year":"2016","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104651_b0070","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbrc.2018.12.127","article-title":"Inhibition of mitochondrial translation as a therapeutic strategy for human ovarian cancer to overcome chemoresistance","volume":"509","author":"Hu","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2026.104651_b0075","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/fcp.12199","article-title":"Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function","volume":"30","author":"Jia","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104651_b0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbrc.2017.01.021","article-title":"Antibiotic tigecycline enhances cisplatin activity against human hepatocellular carcinoma through inducing mitochondrial dysfunction and oxidative damage","volume":"483","author":"Tan","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2026.104651_b0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.pharep.2017.07.007","article-title":"Ciprofloxacin-mediated induction of S-phase cell cycle arrest and apoptosis in COLO829 melanoma cells","volume":"70","author":"Beberok","year":"2018","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.drudis.2026.104651_b0090","first-page":"1727","article-title":"Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53\/Bax\/Bcl-2 signaling pathway","volume":"52","author":"Beberok","year":"2018","journal-title":"Int J Oncol"},{"key":"10.1016\/j.drudis.2026.104651_b0095","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1476-5381.2009.00161.x","article-title":"Ciprofloxacin decreases survival in HT\u201029 cells via the induction of TGF\u2010\u03b21 secretion and enhances the anti\u2010proliferative effect of 5\u2010 fluorouracil","volume":"157","author":"Bourikas","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104651_b0100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1186\/s12885-015-1560-y","article-title":"Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation","volume":"15","author":"Yadav","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drudis.2026.104651_b0105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejphar.2018.08.002","article-title":"GSH depletion, mitochondrial membrane breakdown, caspase-3\/7 activation and DNA fragmentation in U87MG glioblastoma cells: new insight into the mechanism of cytotoxicity induced by fluoroquinolones","volume":"835","author":"Beberok","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104651_b0110","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3892\/ijo.2012.1653","article-title":"Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC","volume":"41","author":"Kloskowski","year":"2012","journal-title":"Int J Oncol"},{"key":"10.1016\/j.drudis.2026.104651_b0115","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bjc.6600079","article-title":"Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells","volume":"86","author":"Herold","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2026.104651_b0120","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3332\/ecancer.2018.886","article-title":"ReDO_DB: the repurposing drugs in oncology database","volume":"12","author":"Pantziarka","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.drudis.2026.104651_b0125","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1701326","article-title":"Antibiotics improve the treatment efficacy of oxaliplatin\u2010based but not irinotecan\u2010based therapy in advanced colorectal cancer patients","volume":"2020","author":"Imai","year":"2020","journal-title":"J Oncol"},{"key":"10.1016\/j.drudis.2026.104651_b0130","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/CMAR.S353432","article-title":"Antibiotic treatment improves the efficacy of oxaliplatin-based therapy as first-line chemotherapy for patients with advanced gastric cancer: a retrospective study","author":"Imai","year":"2022","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.drudis.2026.104651_b0135","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12885-024-11973-9","article-title":"Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: study protocol for a multicenter, randomized phase 2 trial (T-CORE2201)","volume":"24","author":"Imai","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drudis.2026.104651_b0140","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/09546634.2019.1667474","article-title":"Efficacy of doxycycline in the treatment of early stages of mycosis fungoides: a randomized controlled trial","volume":"32","author":"El Sayed","year":"2021","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.drudis.2026.104651_b0145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jbo.2016.06.003","article-title":"A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer","volume":"5","author":"Addison","year":"2016","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.drudis.2026.104651_b0150","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1080\/10428194.2024.2361111","article-title":"A phase ib clinical trial of oral ciprofloxacin and etoposide in subjects with resistant acute myeloid leukemia","volume":"65","author":"Gera","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.drudis.2026.104651_b0155","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1002\/cam4.845","article-title":"A phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia","volume":"5","author":"Reed","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.drudis.2026.104651_b0160","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijrobp.2019.10.010","article-title":"Minocycline reduces chemoradiation-related symptom burden in patients with non-small cell lung cancer: a phase 2 randomized trial","volume":"106","author":"Wang","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.drudis.2026.104651_b0165","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3390\/brainsci13040632","article-title":"Molecular mechanisms of the anti-inflammatory effects of Epigallocatechin 3-Gallate (EGCG) in LPS-activated BV-2 microglia cells","volume":"13","author":"Payne","year":"2023","journal-title":"Brain Sci"},{"key":"10.1016\/j.drudis.2026.104651_b0170","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.3390\/ijms23115938","article-title":"An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases","volume":"23","author":"Teleanu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104651_b0175","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00702-021-02457-2","article-title":"Challenges of repurposing tetracyclines for the treatment of Alzheimer\u2019s and Parkinson\u2019s disease","volume":"129","author":"Markulin","year":"2022","journal-title":"J Neural Transm"},{"key":"10.1016\/j.drudis.2026.104651_b0180","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.3390\/molecules27175481","article-title":"Lipopolysaccharide-induced model of neuroinflammation: mechanisms of action, research application and future directions for its use","volume":"27","author":"Skrzypczak-Wiercioch","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104651_b0185","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104651_b0190","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40035-025-00465-w","article-title":"Second-generation anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: current landscape and future perspectives","volume":"14","author":"Kim","year":"2025","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.drudis.2026.104651_b0195","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1021\/bp060353n","article-title":"Inhibition of amyloid fibrillization of hen egg\u2010white lysozymes by rifampicin and p\u2010benzoquinone","volume":"23","author":"Lieu","year":"2007","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.drudis.2026.104651_b0200","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1006\/bbrc.1994.2428","article-title":"Rifampicin prevents the aggregation and neurotoxicity of amyloid \u03b2 protein in vitro","volume":"204","author":"Tomiyama","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2026.104651_b0205","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1042\/bj3220859","article-title":"Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction","volume":"322","author":"Tomiyama","year":"1997","journal-title":"Biochem J"},{"key":"10.1016\/j.drudis.2026.104651_b0210","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.2042-7158.2011.01309.x","article-title":"Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease","volume":"63","author":"Abuznait","year":"2011","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.drudis.2026.104651_b0215","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/aww042","article-title":"Rifampicin is a candidate preventive medicine against amyloid-\u03b2 and tau oligomers","volume":"139","author":"Umeda","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2026.104651_b0220","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/glia.20268","article-title":"Inhibitory effect of minocycline on amyloid \u03b2 fibril formation and human microglial activation","volume":"53","author":"Familian","year":"2005","journal-title":"Glia"},{"key":"10.1016\/j.drudis.2026.104651_b0225","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pnpbp.2017.03.010","article-title":"Minocycline reduces inflammatory parameters in the brain structures and serum and reverses memory impairment caused by the administration of amyloid \u03b2 (1-42) in mice","volume":"77","author":"Garcez","year":"2017","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.drudis.2026.104651_b0230","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1742-2094-9-62","article-title":"Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology","volume":"9","author":"Ferretti","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.drudis.2026.104651_b0235","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1096\/fj.08-113795","article-title":"Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease","volume":"23","author":"Noble","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.drudis.2026.104651_b0240","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0014-5793(00)02380-2","article-title":"Anti-amyloidogenic activity of tetracyclines: studies in vitro","volume":"487","author":"Forloni","year":"2001","journal-title":"FEBS Lett"},{"key":"10.1016\/j.drudis.2026.104651_b0245","doi-asserted-by":"crossref","first-page":"41647","DOI":"10.1074\/jbc.M111.274548","article-title":"Testing the therapeutic potential of doxycycline in a Drosophila melanogaster model of Alzheimer disease","volume":"286","author":"Costa","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104651_b0250","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.3390\/ijms20184641","article-title":"The anti-amyloidogenic action of doxycycline: a molecular dynamics study on the interaction with A\u03b242","volume":"20","author":"Gautieri","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104651_b0255","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12868-018-0412-5","article-title":"Modulation of the expression of genes related to the system of amyloid-beta metabolism in the brain as a novel mechanism of ceftriaxone neuroprotective properties","volume":"19","author":"Tikhonova","year":"2018","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.drudis.2026.104651_b0260","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/j.neurobiolaging.2015.04.005","article-title":"Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease","volume":"36","author":"Zumkehr","year":"2015","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.drudis.2026.104651_b0265","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3233\/JAD-180708","article-title":"Ceftriaxone improves cognitive function and upregulates GLT-1-related glutamate-glutamine cycle in APP\/PS1 mice","volume":"66","author":"Fan","year":"2018","journal-title":"J Alzheimer's Dis"},{"key":"10.1016\/j.drudis.2026.104651_b0270","article-title":"Inhibition of aggregation of amyloid-\u03b2 through covalent modification with benzylpenicillin; potential relevance to Alzheimer's disease","volume":"26","author":"Alsalahat","year":"2021","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.drudis.2026.104651_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2021.109077","article-title":"Inhibition and disruption of amyloid formation by the antibiotic levofloxacin: a new direction for antibiotics in an era of multi-drug resistance","volume":"714","author":"Khan","year":"2021","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.drudis.2026.104651_b0280","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.trci.2017.05.002","article-title":"Alzheimer's disease drug development pipeline: 2017","volume":"3","author":"Cummings","year":"2017","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.drudis.2026.104651_b0285","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.trci.2018.03.009","article-title":"Alzheimer's disease drug development pipeline: 2018","volume":"4","author":"Cummings","year":"2018","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.drudis.2026.104651_b0290","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","article-title":"Alzheimer's disease drug development pipeline: 2019","volume":"5","author":"Cummings","year":"2019","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.drudis.2026.104651_b0295","article-title":"Alzheimer's disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.drudis.2026.104651_b0300","article-title":"Alzheimer's disease drug development pipeline: 2021","volume":"7","author":"Cummings","year":"2021","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.drudis.2026.104651_b0305","article-title":"Alzheimer's disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.drudis.2026.104651_b0310","article-title":"Alzheimer's disease drug development pipeline: 2023","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.drudis.2026.104651_b0315","article-title":"Alzheimer's disease drug development pipeline: 2024","volume":"10","author":"Cummings","year":"2024","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.drudis.2026.104651_b0320","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1532-5415.2004.52109.x","article-title":"A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease","volume":"52","author":"Loeb","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.drudis.2026.104651_b0325","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/gps.3846","article-title":"A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial","volume":"28","author":"Molloy","year":"2013","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.drudis.2026.104651_b0330","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaneurol.2019.3762","article-title":"Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease: a randomized clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.drudis.2026.104651_b0335","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijid.2016.08.002","article-title":"Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures tested at a large private laboratory network in India, 2008\u20132014","volume":"50","author":"Gandra","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.drudis.2026.104651_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106097","article-title":"Adaptive laboratory evolution of Vibrio cholerae to doxycycline associated with spontaneous mutation","volume":"56","author":"Narendrakumar","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.drudis.2026.104651_b0345","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/00207454.2020.1738432","article-title":"Alzheimer\u2019s disease and gastrointestinal microbiota; impact of Helicobacter pylori infection involvement","volume":"131","author":"Doulberis","year":"2021","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.drudis.2026.104651_b0350","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bph.12139","article-title":"Minocycline: far beyond an antibiotic","volume":"169","author":"Garrido-Mesa","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104651_b0355","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/14740338.2010.495385","article-title":"Atorvastatin: safety and tolerability","volume":"9","author":"Athyros","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.drudis.2026.104651_b0360","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3390\/ph16111615","article-title":"Origin of antibiotics and antibiotic resistance, and their impacts on drug development: a narrative review","volume":"16","author":"Muteeb","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2026.104651_b0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095476","article-title":"Short-term effect of antibiotics on human gut microbiota","volume":"9","author":"Panda","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104651_b0370","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1634\/theoncologist.2019-0160","article-title":"Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer","volume":"25","author":"Tinsley","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.drudis.2026.104651_b0375","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.aah5825","article-title":"Lactobacillus reuteri induces gut intraepithelial CD4+ CD8\u03b1\u03b1+ T cells","volume":"357","author":"Cervantes-Barragan","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104651_b0380","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-020-2865-9","article-title":"Tunable dynamics of B cell selection in gut germinal centres","volume":"588","author":"Nowosad","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104651_b0385","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41590-020-00836-7","article-title":"Gut CD4+ T cell phenotypes are a continuum molded by microbes, not by TH archetypes","volume":"22","author":"Kiner","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.drudis.2026.104651_b0390","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao4755","article-title":"Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis","volume":"10","author":"Scott","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2026.104651_b0395","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.chom.2018.03.002","article-title":"Nutritional support from the intestinal microbiota improves hematopoietic reconstitution after bone marrow transplantation in mice","volume":"23","author":"Staffas","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.drudis.2026.104651_b0400","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1507670","article-title":"Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors","volume":"7","author":"Ahmed","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.drudis.2026.104651_b0405","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2026.104651_b0410","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3390\/jcm10061251","article-title":"Impact of antibiotic therapy and metabolic parameters in non-small cell lung cancer patients receiving checkpoint inhibitors","volume":"10","author":"Castello","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.drudis.2026.104651_b0415","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbi.2015.04.004","article-title":"Gut microbiota depletion from early adolescence in mice: Implications for brain and behaviour","volume":"48","author":"Desbonnet","year":"2015","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.drudis.2026.104651_b0420","doi-asserted-by":"crossref","first-page":"30028","DOI":"10.1038\/srep30028","article-title":"Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer\u2019s disease","volume":"6","author":"Minter","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104651_b0425","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3920\/BM2014.0177","article-title":"Lactobacillus fermentum NS9 restores the antibiotic induced physiological and psychological abnormalities in rats","volume":"6","author":"Wang","year":"2015","journal-title":"Benef Microbes"},{"key":"10.1016\/j.drudis.2026.104651_b0430","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1002\/cam4.5276","article-title":"Growth in eligibility criteria content and failure to accrue among National Cancer Institute (NCI)\u2010affiliated clinical trials","volume":"12","author":"Peterson","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.drudis.2026.104651_b0435","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1177\/00220345870660080401","article-title":"A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity","volume":"66","author":"Golub","year":"1987","journal-title":"J Dent Res"},{"key":"10.1016\/j.drudis.2026.104651_b0440","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/08959374980120010501","article-title":"Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms","volume":"12","author":"Golub","year":"1998","journal-title":"Adv Dent Res"},{"key":"10.1016\/j.drudis.2026.104651_b0445","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ijc.10168","article-title":"Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non\u2010antimicrobial tetracycline analog (COL\u20103) in a metastatic prostate cancer model","volume":"98","author":"Lokeshwar","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drudis.2026.104651_b0450","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1023\/A:1006588708131","article-title":"Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis","volume":"16","author":"Seftor","year":"1998","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.drudis.2026.104651_b0455","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/07347324.2024.2406551","article-title":"10-butyl ether minocycline reduced high alcohol consumption in a dependence mouse model","volume":"43","author":"Panthagani","year":"2025","journal-title":"Alcoholism Treat Q"},{"key":"10.1016\/j.drudis.2026.104651_b0460","doi-asserted-by":"crossref","unstructured":"Shaik AA, et al. Molecular mechanisms of 10-Butyl Ether Minocycline (BEM), a novel non-antibiotic tetracycline, as a potential treatment for inflammatory and neuroimmune-related disorders. BioRxiv. Published online September 15, 2025. https:\/\/doi.org\/10.1101\/2025.06.23.661183.","DOI":"10.1101\/2025.06.23.661183"},{"key":"10.1016\/j.drudis.2026.104651_b0465","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cell.2022.05.009","article-title":"BacPROTACs mediate targeted protein degradation in bacteria","volume":"185","author":"Morreale","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104651_b0470","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-023-06799-7","article-title":"A new antibiotic traps lipopolysaccharide in its intermembrane transporter","volume":"625","author":"Pahil","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104651_b0475","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.3390\/molecules25153409","article-title":"Repurposing drugs to fight hepatic malaria parasites","volume":"25","author":"Fontinha","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104651_b0480","first-page":"14","article-title":"Antimicrobial drug repurposing","volume":"30","author":"Gurajala","year":"2023","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104651_b0485","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3390\/molecules29030635","article-title":"Drug repurposing in the chemotherapy of infectious diseases","volume":"29","author":"Hamid","year":"2024","journal-title":"Molecules"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:23:17Z","timestamp":1785946997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626000565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1359644626000565"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104651","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic repurposing as alternative therapeutic strategies for cancer and Alzheimer\u2019s disease: A solution or conundrum?","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104651","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104651"}}